Can a Patient with Hypertension and Hepatitis B Donate a Kidney?
A patient with well-controlled hypertension (BP <140/90 mmHg on ≤2 medications) and hepatitis B can potentially donate a kidney, but this requires careful individualized assessment based on specific donor characteristics, recipient matching, and institutional risk thresholds.
Hypertension in Living Kidney Donors
The presence of hypertension does not automatically disqualify a potential living kidney donor, but acceptance depends on multiple factors 1, 2:
Blood Pressure Requirements
- Donors must have at least 2 office measurements documenting systolic BP <140 mmHg and diastolic BP <90 mmHg 2
- For ambulatory monitoring: mean awake BP <135/85 mmHg and sleep BP <120/75 mmHg 2
- More recent guidelines suggest lower targets (130/80 mmHg), though no absolute consensus exists 1
Favorable Donor Profile for Hypertensive Candidates
Research suggests hypertensive donors can proceed safely when they meet specific criteria 3:
- Age >50 years
- BMI 26-30 kg/m² (non-obese)
- No evidence of end-organ damage
- Well-controlled on 1-2 antihypertensive medications
- Predominantly studied in white donors
Critical Caveat
There are no safety data on living kidney donation among non-white donors (Hispanic and African American) with predonation hypertension controlled with medications 1. This represents a significant knowledge gap, as African Americans have increased risk of post-donation hypertension 1.
Required Counseling
Hypertensive donor candidates must be informed that 1:
- Blood pressure may rise with aging
- Donation may accelerate the rise in BP beyond normal aging expectations
- Lifelong antihypertensive treatment may become necessary
Hepatitis B in Living Kidney Donors
The hepatitis B status creates a more complex scenario:
Traditional Approach
- Hepatitis B surface antigen (HBsAg)-positive donors are typically contraindicated for HBsAg-negative recipients 2
- HBsAg-positive status has historically been considered an absolute contraindication for standard donation
Emerging Evidence for Matched Donation
Recent high-quality evidence suggests a paradigm shift is occurring 4:
When HBsAg-positive donors are intentionally used for appropriately selected recipients:
- Overall HBV transmission rate: 4.0% (95% CI: 1.8%-8.3%)
- Most transmissions (62%) were transient low-level viremia only
- Transmission rates drop to 1.4% when recipients have positive surface antibody (>10 IU/L)
- Transmission rates are only 0.8% with living donors
Risk Stratification for HBV-Positive Donation
Higher transmission risk occurs when 4:
- Donor has positive nucleic acid test (NAT): 16.0% transmission rate
- Recipient lacks surface antibody protection
Lower transmission risk occurs when 4:
- Living donor (vs. deceased): 0.8% transmission rate
- Recipient has positive surface antibody: 1.4% transmission rate
- Recipient receives antiviral prophylaxis
Critical Safety Consideration
Three deaths from HBV transmission occurred in the literature, all among recipients NOT taking post-transplant antiviral prophylaxis 4. This underscores the absolute necessity of prophylaxis protocols.
Matched Serology Donation
Multiple studies support HBsAg-positive to HBsAg-positive matched donation 5, 6, 7:
- Dramatically shortens waiting time (8 months vs. 3 years) 7
- Patient and graft survival rates of 100% in short-term follow-up 5, 7
- Requires careful post-transplant monitoring for viral reactivation
- Long-term liver disease progression remains a concern requiring ongoing study 6
Integrated Decision Algorithm
Step 1: Assess Hypertension Eligibility
- Confirm BP <140/90 mmHg on ≤2 medications
- Age ideally >50 years
- BMI <30 kg/m² (preferably 26-30)
- No end-organ damage (normal urinalysis, no proteinuria, normal cardiac evaluation)
- Consider cardiac stress testing given hypertension history 2
Step 2: Assess Hepatitis B Status and Recipient Matching
If HBsAg-positive:
- Determine donor NAT status
- Only proceed if recipient is also HBsAg-positive (matched serology) for standard practice
- OR consider for HBsAg-negative recipients ONLY if:
- Recipient has protective surface antibody (>10 IU/L)
- Mandatory antiviral prophylaxis protocol in place
- Institutional protocol for HBV-positive donation exists
- Comprehensive informed consent obtained
- Close post-transplant monitoring established
If HBsAg-negative but surface antibody positive:
- This is NOT a contraindication 2
- Proceed with standard evaluation
Step 3: Combined Risk Assessment
The combination of hypertension AND hepatitis B requires:
- Transplant program's acceptable risk threshold must be explicitly defined 1
- Consider that both conditions independently affect long-term outcomes
- Ensure comprehensive informed consent addressing both risk factors
- Establish enhanced long-term monitoring protocols
Common Pitfalls to Avoid
Assuming all HBV-positive donors are automatically excluded - Matched serology donation is increasingly accepted 4, 5, 6, 7
Failing to obtain NAT testing in HBsAg-positive donors - NAT status significantly affects transmission risk 4
Proceeding with HBV-positive to HBV-negative donation without antiviral prophylaxis - This has resulted in deaths 4
Accepting hypertensive donors without assessing for end-organ damage - Proteinuria, abnormal cardiac findings, or other complications are contraindications
Not counseling about accelerated BP rise post-donation - This is a known risk that donors must understand 1
Bottom Line
For your specific patient with both hypertension and hepatitis B: donation may be possible if (1) hypertension is well-controlled (<140/90 mmHg on ≤2 medications), (2) the patient is >50 years old with no end-organ damage, and (3) there is an HBsAg-positive recipient available for matched donation, OR an institutional protocol exists for HBV-positive donation with mandatory recipient vaccination/prophylaxis and monitoring. This decision must align with your transplant program's risk threshold and requires comprehensive informed consent addressing both conditions 1, 4.